C. Fegan

C. Fegan, A. Bradbury, P. Burns, 2002, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

C. Fegan, P. Fischer, Shudong Wang, 2013, Oncotarget.

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

T. Stankovic, C. Fegan, R. Hills, 2008, Blood.

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.

M. Dyer, C. Fegan, R. Hills, 2011, Leukemia research.

Evaluation of erythropoiesis after bone marrow transplantation: quantitative reticulocyte counting

C. Fegan, I. Cavill, N. Bentley, 1992, British journal of haematology.

Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens

M. Wise, C. Fegan, B. Morgan, 2020, Annals of clinical biochemistry.

The association between raised coagulation factor levels and venous thrombo-embolism.

C. Fegan, A. Bradbury, D. Adam, 2005, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.

C. Fegan, P. Crooks, P. Brennan, 2008, Blood.

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis.

C. Fegan, G. Pratt, D. Baird, 2010, Blood.

Eradication of minimal residual disease improves overall and progression‐free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation

W. Gregory, C. Fegan, G. Follows, 2017, British journal of haematology.

CLL: a supplementary question?

C. Fegan, C. Pepper, 2011, Blood.

The vitamin D 3 analog EB 1089 induces apoptosis via a p 53-independent mechanism involving p 38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro

C. Fegan, D. Milligan, C. Pepper, 2003 .

The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro.

C. Fegan, D. Milligan, C. Pepper, 2003, Blood.

The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial.

C. Fegan, T. Marshall, A. Bradbury, 2007, Journal of Vascular Surgery.

The incidence of raised procoagulant factors and hyperhomocysteinaemia in Chinese patients with chronic venous insufficiency.

C. Fegan, A. Bradbury, D. Adam, 2010, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia

A. Pettitt, C. Fegan, G. Follows, 2012, British journal of haematology.

Telomere length is an independent prognostic marker in MDS but not in de novo AML

C. Fegan, R. Hills, D. Bowen, 2017, British journal of haematology.

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology

M. Nöthen, H. Goldschmidt, O. Stephens, 2018, Blood Cancer Journal.

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

G. Salles, M. Dyer, C. Fegan, 2019, Leukemia.

Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia

A. Pettitt, P. Broderick, R. Houlston, 2010, Leukemia.

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

M. Dyer, C. Fegan, S. Rule, 2020, Clinical Cancer Research.

South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to White patients

C. Fegan, P. Moss, B. Austen, 2008, British journal of haematology.

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

T. Stankovic, C. Fegan, P. Moss, 2005, Blood.

Outpatient management of DVT using low molecular weight heparin and a hospital outreach service.

C. Fegan, W. Lester, N. Rymes, 2002, Clinical and laboratory haematology.

Exercise in claudicants is accompanied by excessive thrombin generation.

C. Fegan, A. Bradbury, P. Burns, 2003, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Leukemic and Non-Leukemic Lymphocytes from Patients with Li Fraumeni Syndrome Demonstrate Loss of p53 Function, Bcl-2 Family Dysregulation and Intrinsic Resistance to Conventional Chemotherapeutic Drugs But Not Flavopiridol

C. Fegan, C. Pepper, T. Hoy, 2003, Cell cycle.

The outcome of ambulatory DVT management using a multidisciplinary approach.

C. Fegan, D. O'shaughnessy, P. Rose, 2001, Clinical and laboratory haematology.

Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor

S. Greenfield, C. Fegan, C. Pepper, 2017, Oncotarget.

The constitutive procoagulant and hypofibrinolytic state in patients with intermittent claudication due to infrainguinal disease significantly improves with percutaneous transluminal balloon angioplasty.

C. Fegan, T. Marshall, A. Bradbury, 2006, Journal of vascular surgery.

Pulmonary infection with Nocardia caviae in a patient with diabetes mellitus and liver cirrhosis.

C. Fegan, B. Salh, A. Jaulim, 1988, Thorax.

Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells

C. Fegan, J. Hartley, H. Lowe, 2007, British Journal of Cancer.

Antigenaemia during acute graft versus host disease.

C. Fegan, S. Jackson, J. Whittaker, 1995, Journal of clinical pathology.

The Novel Nuclear Factor-κB Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine

C. Fegan, P. Brennan, C. Jordan, 2008, Clinical Cancer Research.

Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.

C. Fegan, R. Hills, P. Brennan, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

All trans retinoic acid enhances human LAK activity

C. Fegan, J. Whittaker, T. Hoy, 1995, European journal of haematology.

for myeloid leukaemia following HLA-identical sibling haematopoietic stem cell transplantation The impact of donor KIR and patient HLA-C genotypes on outcome

C. Craddock, C. Fegan, P. Moss, 2013 .

Telomere length is a critical determinant for survival in multiple myeloma

C. Fegan, R. Hills, J. Allan, 2017, British journal of haematology.

Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation.

C. Craddock, C. Fegan, P. Moss, 2005, Blood.

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Patricia A. H. Williams, Steve B Jones, K. Y. Wong, 2021, The Lancet.

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

T. Shanafelt, C. Fegan, D. Rossi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD 49 d Is the Strongest Flow Cytometry – Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia

T. Shanafelt, C. Fegan, D. Rossi, 2014 .

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses.

G. Morgan, C. Fegan, C. McConkey, 2005, Blood.

Guidelines on the diagnosis and management of chronic lymphocytic leukaemia

C. Fegan, P. Maguire, D. Oscier, 2004, British journal of haematology.

Serum erythropoietin during autologous bone marrow transplantation: relationship to measures of erythroid activity.

C. Fegan, I. Cavill, Y. Beguin, 1995, Clinical and Laboratory Haematology.

Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration.

C. Fegan, M. S. Longhi, C. Pepper, 2016, Blood.

Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery.

C. Fegan, P. Moss, V. Mautner, 2002, Blood.

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

E. Kimby, C. Fegan, G. Hale, 2004, Blood.

Flavopiridol circumvents Bcl‐2 family mediated inhibition of apoptosis and drug resistance in B‐cell chronic lymphocytic leukaemia

C. Fegan, C. Pepper, T. Hoy, 2001, British journal of haematology.

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

C. Fegan, D. Oscier, A. Rawstron, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

raction with Vascular Endothelium Enhances Survival in ary Chronic Lymphocytic Leukemia Cells via NF-κB

C. Fegan, C. Pepper, N. S. Thomas, 2010 .

Cancer esearch cular and Cellular Pathobiology raction with Vascular Endothelium Enhances Survival in ary Chronic Lymphocytic Leukemia Cells via NF-κ B R ivation and De novo Gene Transcription

C. Fegan, C. Pepper, N. S. Thomas, 2010 .

A phase I trial of the PARP inhibitor olaparib in patients with relapsed or refractory Chronic Lymphocytic Leukaemia, T-Prolymphocytic Leukaemia or Mantle Cell Lymphoma

A. Pettitt, M. Dyer, T. Stankovic, 2018 .

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies

C. Fegan, D. Catovsky, J. Polesel, 2021, Leukemia.

The clinical outcome and toxicity of high‐dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study

C. Fegan, J. Byrne, J. Snowden, 2006, British journal of haematology.

Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias.

T. Stankovic, G. Stewart, C. Fegan, 2003, The American journal of pathology.

CD38+ chronic lymphocytic leukaemia cells co-express high levels of ZAP-70 and are functionally distinct from their CD38− counter-parts

C. Fegan, P. Brennan, G. Pratt, 2006, Leukemia.

A polymorphism in the 3′ UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma

C. Fegan, A. Hall, J. Allan, 2010, British journal of haematology.

Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology

G. Morgan, S. Rollinson, C. Fegan, 2002, British journal of haematology.

Understanding cancer cell survival is key to patient survival.

C. Fegan, C. Pepper, 2015, The Lancet. Oncology.

Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease

C. Fegan, R. Hills, J. Allan, 2014, British journal of haematology.

Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia.

C. Fegan, P. Brennan, S. Khanna, 2014, Journal of proteome research.

The NF-κB Inhibitor LC-1 Has Single Agent Activity in Multiple Myeloma Cells and Synergizes with Bortezomib

C. Fegan, P. Crooks, A. Burnett, 2010, Molecular Cancer Therapeutics.

Respiratory failure during induction chemotherapy for acute myelomonocytic leukaemia (FAB M4Eo) with Ara‐C and all‐trans retinoic acid

C. Fegan, W. Lester, T. Morris, 2000, British journal of haematology.

Mantle cell leukaemia?

C. Fegan, D. Milligan, J. Neilson, 1996, British journal of haematology.

Is venetoclax a new wonder drug in CLL?

C. Fegan, C. Pepper, 2019, British journal of haematology.

Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation.

D. Pillay, C. Fegan, S. Mackinnon, 2003, Blood.

Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease.

C. Fegan, P. Thompson, J. Whittaker, 1995, Leukemia.

transplantation cytomegalovirus reactivation following T-cell replete stem cell genotype has a major influence on the rate of KIR Donor

C. Craddock, C. Fegan, P. Moss, 2012 .

Early discharge and home supervision of patients with pulmonary embolism treated with low-molecular weight heparin.

D. Parr, C. Fegan, D. Stableforth, 2003, European journal of internal medicine.

Higher prevalence of thrombophilia in patients with varicose veins and venous ulcers than controls.

C. Fegan, A. Bradbury, D. Adam, 2009, Journal of vascular surgery.

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

Jennifer L. Bell, M. Landray, P. Horby, 2020, medRxiv.

Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia.

C. Fegan, P. Brennan, G. Pratt, 2014, Blood.

Effect of IgM‐enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti‐endotoxin antibodies in bone marrow transplantation

C. Fegan, J. Parton, R. Barnés, 1993, European journal of clinical investigation.

ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele

M. Dyer, T. Stankovic, C. Fegan, 2012, Haematologica.

Highly purified CD38+ sub‐populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38− sub‐populations derived from the same chronic lymphocytic leukaemia patient

C. Fegan, G. Pratt, D. Baird, 2008, British journal of haematology.

C‐myc amplification, double minutes and homogenous staining regions in a case of AML

C. Fegan, D. White, C. Fegan, 1995, British journal of haematology.

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia

C. Fegan, D. Rossi, A. Neri, 2019, Haematologica.

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition

C. Fegan, F. Stevenson, G. Pratt, 2014, Leukemia.

damage response and unrepaired chromosome damage leukemia occurs in pregerminal center cells and results in defective deficient B-cell chronic lymphocytic - Ataxia telangiectasia mutated

T. Stankovic, G. Stewart, P. Byrd, 2013 .

Mimicking the tumour microenvironment: three different co‐culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells

C. Fegan, P. Brennan, E. Hamilton, 2012, British journal of haematology.

Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38

C. Fegan, S. Deaglio, P. Brennan, 2010, Haematologica.

Highly purified CD38+ and CD38− sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin

C. Fegan, K. Mills, P. Brennan, 2007, Leukemia.

Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.

C. Fegan, G. Pratt, D. Milligan, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage

T. Stankovic, C. Fegan, D. Oscier, 2012, Leukemia.

Haemostatic and fibrinolytic responses to bone marrow transplantation

C. Fegan, J. Giddings, J. Whittaker, 1999, British journal of haematology.

Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci

A. Pettitt, H. Goldschmidt, G. Morgan, 2017, Scientific Reports.

Telomere analysis to predict chronic lymphocytic leukemia outcome: a STELA test to change clinical practice?

C. Fegan, D. Baird, C. Pepper, 2014, Expert review of hematology.

Common variants at 2q37.3, 8q24.21, 15q21.3, and 16q24.1 influence chronic lymphocytic leukemia risk

E. Campo, E. Montserrat, A. Pettitt, 2010, Nature Genetics.

Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia

J. Cerhan, T. Shanafelt, S. Slager, 2016, American journal of hematology.

a supplementary question?

C. Fegan, 2011 .

Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same CLL-IPI Score

T. Shanafelt, C. Fegan, N. Kay, 2018, Blood.

Increased frequency of CD4+PD‐1+HLA‐DR+ T cells is associated with disease progression in CLL

C. Fegan, R. Hills, C. Pepper, 2019, British journal of haematology.

Parenteral glutamine protects hepatic function during bone marrow transplantation

C. Fegan, J. Giddings, J. Whittaker, 1998, Bone Marrow Transplantation.

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

A. Pettitt, C. Fegan, C. Dearden, 2007 .

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.

A. Pettitt, C. Fegan, C. Yap, 2020, Haematologica.

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

J. Gribben, A. Pettitt, C. Fegan, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL

J. Gribben, A. Pettitt, C. Fegan, 2017, Leukemia.

Natural‐Product‐Like Spiroketals and Fused Bicyclic Acetals as Potential Therapeutic Agents for B‐Cell Chronic Lymphocytic Leukaemia

C. Fegan, G. Prencipe, S. Ley, 2008, ChemMedChem.

p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia

J. James, A. Prescott, C. Fegan, 2013, British Journal of Cancer.

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.

C. Fegan, S. Mackinnon, G. Hale, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Respiratory virus infections in transplant recipients after reduced‐intensity conditioning with Campath‐1H: high incidence but low mortality

C. Fegan, S. Mackinnon, G. Hale, 2002, British journal of haematology.

immunosuppression, and immune recovery incidence and outcome in relation to graft manipulation, Adenovirus infections following allogeneic stem cell transplantation:

C. Fegan, P. Moss, V. Mautner, 2013 .

T‐cell depletion with Campath‐1H ‘in the bag’ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft‐versus‐host disease, rapid immune constitution and improved survival

C. Fegan, G. Hale, H. Waldmann, 2003, British journal of haematology.

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

J. Gribben, A. Pettitt, C. Fegan, 2018, Blood.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.

C. Fegan, J. Hartley, M. Suggitt, 2010, Cancer research.

The Novel Sequence-Specific DNA Cross-Linking Agent SJG-136 (NSC 694501) Has Potent and Selective In vitro Cytotoxicity in Human B-Cell Chronic Lymphocytic Leukemia Cells with Evidence of a p53-Independent Mechanism of Cell Kill

C. Fegan, C. Pepper, P. Delavault, 2004, Cancer Research.

Cerebral toxoplasmosis in a patient with chronic lymphocytic leukaemia treated with fludarabine

C. Fegan, S. Bacchu, J. Neal, 2007, British journal of haematology.

Lesson of the Week: ANY QUESTIONS

C. Fegan, 1995 .

reconstitution cell transplantation: potential role of Campath-1H in delaying immune High incidence of cytomegalovirus infection after nonmyeloablative stem

C. Fegan, S. Mackinnon, K. Peggs, 2008 .

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

C. Craddock, C. Fegan, S. Mackinnon, 2002, Blood.

Beta2‐microglobulin is a better predictor of treatment‐free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate

Julio Delgado, Guy Pratt, J. Briones, 2009, British journal of haematology.

Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma

C. Fegan, S. Mitchell, S. Mackay, 2022, Cancers.

Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia

C. Fegan, P. Brennan, M. Premanathan, 2021, Electronic Journal of Biotechnology.

Defining the prognosis of early stage chronic lymphocytic leukaemia patients

Chris Pepper, Aneela Majid, Thet Thet Lin, 2012, British journal of haematology.

NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia.

C. Fegan, P. Brennan, C. Pepper, 2009, Future oncology.

The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia

J. Delgado, C. Fegan, G. Pratt, 2006, Cancer.

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

David P Lane, T. Stankovic, C. Fegan, 2005, Blood.

Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.

T. Stankovic, G. Stewart, P. Byrd, 2004, Blood.

Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD / SCID mice

T. Stankovic, G. Stewart, P. Byrd, 2002 .

Mapping the human genetic architecture of COVID-19

Mattia G. Bergomi, Christopher M. DeBoever, Matthew A. Wiles, 2021, Nature.

A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia

Guy Pratt, Richard S Houlston, Claire Dearden, 2008, Nature Genetics.

Elucidation of Focal Adhesion Kinase as a Modulator of Migration and Invasion and as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia

C. Fegan, S. Mitchell, Benjamin P Towler, 2022, Cancers.

lymphocytic leukemia Role for CCG-trinucleotide repeats in the pathogenesis of chronic

C. Fegan, D. Syndercombe-Court, R. Müllenbach, 2013 .

Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia

C. Fegan, F. Bertoni, F. Cotter, 2005, Genes, chromosomes & cancer.

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

T. Stankovic, C. Fegan, D. Catovsky, 2015, Leukemia.

The P2X7 receptor gene polymorphism 1513 A→C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl‐2 family protein expression or survival in B‐cell chronic lymphocytic leukaemia

Guy Pratt, C. Fegan, G. Pratt, 2003, British journal of haematology.

Molecular abnormalities in B-cell chronic lymphocytic leukaemia.

C. Fegan, 2001, Clinical and laboratory haematology.

The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire.

C. Fegan, P. Moss, L. Billingham, 2010, Blood.

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

G. Salles, M. Dyer, C. Fegan, 2016, Blood.

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia

Aneela Majid, Guy Pratt, Göran Roos, 2013, Nature Genetics.

Thrombophilia, polymorphisms, and vascular disease

C. Fegan, T. Sykes, D. Mosquera, 2000, Molecular pathology : MP.

Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection

M. Wise, R. Stanton, C. Fegan, 2020, Function.

Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation.

C. Fegan, S. Jackson, R. Barnes, 1992, Bone marrow transplantation.

Clinical utility of telomere length measurements in cancer.

C. Fegan, C. Pepper, K. Norris, 2020, Current opinion in genetics & development.

Oral vitamin B12 can change our practice

C. Fegan, S. Daly, P. Nightingale, 2003, Postgraduate medical journal.

Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia.

J. Delgado, C. Fegan, G. Pratt, 2006, Leukemia research.

The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia

L. Hiller, C. Fegan, G. Pratt, 2006, Leukemia & lymphoma.

Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length

G. Morgan, D. Auclair, C. Fegan, 2021, Leukemia.

Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression

C. Fegan, M. Mason, C. Pepper, 2011, Clinical Cancer Research.

A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel)

H. Ramroth, C. Fegan, T. Nicholson, 2021, British journal of haematology.

Chronic lymphocytic leukaemia: one cell, two diseases?

C. Fegan, 2002, The Lancet.

Telomere length predicts for outcome to FCR chemotherapy in CLL

C. Fegan, R. Hills, D. Baird, 2019, Leukemia.

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.

G. Salles, M. Dyer, C. Fegan, 2017, Blood.

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

J. Gribben, A. Pettitt, C. Fegan, 2017 .

Telomere fusions associate with coding sequence and copy number alterations in CLL

C. Fegan, K. Ashelford, D. Baird, 2019, Leukemia.

Guideline for the treatment of chronic lymphocytic leukaemia

A. Pettitt, C. Fegan, G. Follows, 2018, British journal of haematology.

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19

M. Wise, C. Fegan, B. Morgan, 2020, American journal of respiratory and critical care medicine.

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

C. Fegan, D. Oscier, A. Rawstron, 2007 .

TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target.

Christopher I. Jones, T. Chevassut, T. Stankovic, 2021, Blood.

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia

A. Pettitt, M. Dyer, R. Houlston, 2021, Nature communications.

A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL

C. Fegan, C. Pepper, Eva-Maria Nichols, 2015, Oncotarget.

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

A. Pettitt, J. Radford, C. Fegan, 2011, British journal of haematology.

Genetic screening for hemochromatosis: a cautionary tale.

C. Fegan, G. Pratt, J. Starczynski, 2005, Clinical chemistry.

Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies

G. Salles, B. Cheson, M. Dyer, 2016 .

Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells

C. Fegan, P. Brennan, C. Pepper, 2013, Haematologica.

CD8+ T-cell recognition of a synthetic epitope formed by t-butyl modification

C. Fegan, P. Rizkallah, C. Pepper, 2015, Immunology.

The gut mucosal barrier in bone marrow transplantation.

C. Fegan, J. Whittaker, C. Poynton, 1990, Bone marrow transplantation.

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma

G. Salles, M. Dyer, J. Radford, 2020, Leukemia.

Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia

R. Holder, C. Fegan, G. Mead, 2009, British journal of haematology.

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.

D. Dunlop, C. Fegan, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells

C. Fegan, A. Burnett, C. Pepper, 2012, Oncotarget.

The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion

C. Fegan, J. Farmer, S. Shigdar, 2003, Eye.

Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF-κB Inhibitory Capacity of Pyrrolobenzodiazepines (PBDs).

C. Fegan, S. Jamshidi, C. Pepper, 2019, Journal of medicinal chemistry.

A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma

A. Pettitt, M. Dyer, T. Stankovic, 2018, British journal of haematology.

Haemolytic anaemia following treatment with piperacillin in a patient with cystic fibrosis.

C. Fegan, K. Thickett, M. Wildman, 1999, The Journal of antimicrobial chemotherapy.

Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit.

C. Fegan, M. Galiano, A. Lackenby, 2011, The Journal of infectious diseases.

Leucocyte Antigen Facts Book

C. Fegan, 1997 .

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

J. Gribben, A. Pettitt, C. Fegan, 2020 .

BAX UTR G (-248) A Polymorphism Has No Impact on Survival in Patients with Multiple Myeloma.

G. Morgan, C. Fegan, F. Davies, 2006 .

The role of the bax gene polymorphism G(−248)A in chronic lymphocytic leukemia

C. Fegan, G. Pratt, J. Starczynski, 2006, Leukemia.

Retinoid‐induced apoptosis in B‐cell chronic lymphocytic leukaemia cells is mediated through caspase‐3 activation and is independent of p53, the retinoic acid receptor, and differentiation

C. Fegan, C. Pepper, T. Hoy, 2002, European journal of haematology.

Trinucleotide repeat dynamic mutation identifying susceptibility in familial and sporadic chronic lymphocytic leukaemia

C. Fegan, N. Caporaso, D. Syndercombe-Court, 2007, British journal of haematology.

Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit nuclear factor-κB activity and synergize with bortezomib and ibrutinib in hematologic cancers

C. Fegan, K. Ashelford, C. Pepper, 2020, Haematologica.

Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF B activity and synergise with bortezomib and κ ibrutinib in hematological cancers

C. Fegan, P. Giles, C. Pepper, 2020 .

The safety and effectiveness of a nurse-led anticoagulant service.

C. Fegan, C. Wright, C. Connor, 2002, Journal of advanced nursing.

Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD.

S. Futaki, C. Fegan, P. Brennan, 2009, Journal of controlled release : official journal of the Controlled Release Society.

Central retinal vein occlusion and thrombophilia

C. Fegan, C. Fegan, 2002, Eye.

Human Cancer Biology Expansion of a CD 8 þ PD-1 þ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD 4 : CD 8 Ratios and Disease Progression

C. Fegan, M. Mason, C. Pepper, 2012 .

Expansion of a CD 8 þ PD-1 þ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD 4 : CD 8 Ratios and Disease Progression

C. Fegan, M. Mason, C. Pepper, 2011 .

The role of tissue factor in patients undergoing open repair of ruptured and nonruptured abdominal aortic aneurysms.

C. Fegan, A. Bradbury, D. Adam, 2007, Journal of vascular surgery.

Trained nurses can obtain satisfactory bone marrow aspirates and trephine biopsies.

C. Fegan, D. Milligan, S. Lawson, 1999, Journal of clinical pathology.

Transplant Donor KIR Genotype Influences the Rate of CMV Reactivation Following T-Replete Stem Cell Transplantation.

C. Craddock, C. Fegan, P. Moss, 2004 .

Systematic Shortening of Noncovalent C 8 Side Chain on the Cytotoxicity and NF-κ B Inhibitory Capacity of Pyrrolobenzodiazepines ( PBDs )

C. Fegan, S. Jamshidi, C. Pepper, 2019 .

Karyotypic andmolecular abnormalities in chronic lymphocytic leukaemia

C. Fegan, 1996 .

BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib

M. Dyer, C. Fegan, S. Jayne, 2023, Blood advances.

5.46 NCRN CLL207 Study of Alemtuzumab Consolidation in Chronic Lymphocytic Leukaemia: Response Assessment Follow-up and Pharmacokinetic studies (on Behalf of the NCRI CLL Trials Sub-Group)

W. Gregory, C. Fegan, G. Follows, 2011 .

A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.

M. Dyer, T. Brümmendorf, J. Radford, 2018 .

SPONTANEOUS REMISSION IN A PATIENT WITH CHRONIC MYELOID LEUKAEMIA

C. Fegan, J. Whittaker, G. Morgan, 1989, British Journal of Haematology.

Enterovirus infections following T-cell depleted allogeneic transplants in adults

C. Fegan, D. Milligan, D. Milligan, 2004, Bone Marrow Transplantation.

Mapping the human genetic architecture of COVID-19

Mattia G. Bergomi, Christopher M. DeBoever, Matthew A. Wiles, 2021, Nature.

A common low penetrance risk allele for chronic lymphocytic leukaemia in the 3’ UTR of IRF4/MUM1 predicts prognosis independent of 1gVH status.

A. Pettitt, R. Houlston, C. Fegan, 2010 .

Menetrier's disease complicated by development of the Zollinger—Ellison syndrome

C. Fegan, J. Sunter, I. A. Miller, 1985, The British journal of surgery.

Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia

G. Salles, M. Dyer, C. Fegan, 2016 .

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

James G. Wright, M. Dyer, C. Fegan, 2013 .

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

James G. Wright, G. Salles, M. Dyer, 2013 .

Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy?

D. Pillay, C. Fegan, D. Milligan, 2000, Bone Marrow Transplantation.

CLL: a supplementary question?

C. Fegan, C. Pepper, 2011, Blood.

Prognostic Relevance of CD49d Expression On B Leukemic Cells in Chronic Lymphocytic Leukemia. Meta-Analysis of Published and unpublished Individual Data From 3146 Patients

T. Shanafelt, C. Fegan, D. Rossi, 2012 .

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia

A. Pettitt, C. Fegan, G. Follows, 2012, British journal of haematology.

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

K. C. Morris, Michele R. Shaw, Mohammed Salah Ibrahim, 2023, The Lancet.

Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.

C. Fegan, R. Hills, P. Brennan, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

T. Stankovic, C. Fegan, R. Hills, 2008, Blood.

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

J. Gribben, A. Pettitt, C. Fegan, 2022, Blood.

Beta2‐microglobulin is a better predictor of treatment‐free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate

J. Briones, J. Delgado, A. Aventín, 2009, British journal of haematology.

SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.

C. Fegan, J. Hartley, M. Suggitt, 2010, Cancer research.

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy

C. Fegan, M. Donia, I. Svane, 2023, Cell.

Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD.

S. Futaki, C. Fegan, P. Brennan, 2009, Journal of controlled release : official journal of the Controlled Release Society.

Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study

C. Fegan, D. Milligan, D. Milligan, 2001, Bone Marrow Transplantation.